Overview

Nanobodies Market Overview:

Nanobodies are single domain antibodies derived from heavy-chain antibodies in mammals that have unique properties such as nanoscale size, robust structure, stable and soluble behaviours in aqueous solution, reversible protein refolding, high affinity and specificity for only one cognate target, and more. Nanobodies are used in a wide range of applications, from fundamental science to clinical therapies. Nanobodies are employed as affinity capture reagents because of their tiny size and single domain chain nanobodies have a greater binding surface and reduced nonspecific background binding. Nanobodies can also be utilised to treat cancer and other diseases by limiting ligand-receptor interactions, such as blocking anti-von Willebrand factor to avoid thrombosis or anti-TNF- to treat arthritis. To monitor antigen activity, nanobodies can be produced inside cells and coupled with a fluorescent protein. Nanobodies are excellent protein stabilisers, which is especially crucial during protein crystallisation. Because of their capacity to lock proteins in a specific shape and stabilise flexible regions, nanobodies are utilised in a variety of protein crystallisation research. This boosts nanobodies acceptance and, as a result, the market for nanobodies expands. Aarhus University scientists, for example, produced nanobodies on October 2, 2017. This opens up a direct path to solving novel X-ray crystal structures of protein complexes for better understanding of biological processes, which is crucial for medication development.

As recombinant variable domains of heavy-chain-only antibodies, nanobodies possess a number of unique properties including tininess, excellent solubility, superior stability, quick clearance from blood, and deep tissue penetration. Therefore, nanobodies are becoming a promising diagnostic and therapeutic tool. Nanobodies, as imaging tracers, allow the early acquisition of high-quality images, provide a comprehensive evaluation of the condition, and then proceed to enable personalized precision therapy. As therapeutic agents, nanobodies enable targeted therapy by delivering lesion-specific drugs and effector domains to the site of lesion, thus improving the specificity and efficacy of the treatment.

FutureWise Market Research has instantiated a report that provides an intricate analysis of Nanobodies Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the Nanobodies Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

Major players included in the Nanobodies Market:
• Novo Nordisk A/S
• Merck & Co., Inc.
• Merck KGaA
• AbbVie, Inc.
• C.H. Boehringer Sohn AG & Ko. KG.
(Note: The list of the major players will be updated with the latest market scenario and trends)

Nanobodies Market Segmentation:
By Product Type
• Mono-specific
 o Monovalent
 o Multivalent
 o Bi-paratopic
• Multi-specific
By Indication
• Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
• Respiratory Syncytial Virus (RSV) Infection
• Rheumatoid Arthritis
• Systemic Lupus Erythematosus
• Oncology
• Immune Mediated Inflammatory Diseases (IMID)
• Psoriasis
• Chronic Kidney Diseases
• Bone Disorders
• Others
By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Nanobodies Market Sample Video:

Competitive Landscape:
• Tier 1 players- established companies in the market with a major market share
• Tier 2 players
• Emerging players which are growing rapidly
• New Entrants

FutureWise Key Takeaways:
• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:
• To provide with an exhaustive analysis on the Nanobodies Market By Product Type, By Indication, By Distribution Channel and By Region.
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:
• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization Mobility Care offered are free of charge with purchase of any license of the report
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Global Nanobodies Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Nanobodies Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Nanobodies Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Nanobodies Market, By Product Type Historical Analysis and Forecast 2022-2028 (USD Million)
   7.1. Mono-specific
        7.1.1. Monovalent
        7.1.2. Multivalent
        7.1.3. Bi-paratopic
   7.2. Multi-specific

8. Global Nanobodies Market, By Indication Historical Analysis and Forecast 2022-2028 (USD Million)  
   8.1. Acquired Thrombotic Thrombocytopenic Purpura (aTTP)
   8.2. Respiratory Syncytial Virus (RSV) Infection
   8.3. Rheumatoid Arthritis
   8.4. Systemic Lupus Erythematosus
   8.5. Oncology
   8.6. Immune Mediated Inflammatory Diseases (IMID)
   8.7. Psoriasis
   8.8. Chronic Kidney Diseases
   8.9. Bone Disorders
   8.10.Others

9. Global Nanobodies Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
   9.1. Hospital Pharmacies
   9.2. Retail Pharmacies
   9.3. Online Pharmacies

10. North America Nanobodies Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Nanobodies Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Nanobodies Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Nanobodies Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. Saudi Arabia
          14.2.2. UAE
          14.2.3. South Africa
          14.2.4. Egypt
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    16.1. Novo Nordisk A/S
          16.1.1. Company Overview
          16.1.2. Product Portfolio
          16.1.3. SWOT Analysis
          16.1.4. Financial Overview
          16.1.5. Strategic Overview
    16.2. Merck & Co., Inc.
          16.2.1. Company Overview
          16.2.2. Product Portfolio
          16.2.3. SWOT Analysis
          16.2.4. Financial Overview
          16.2.5. Strategic Overview 
    16.3. Merck KGaA.
          16.3.1. Company Overview
          16.3.2. Product Portfolio
          16.3.3. SWOT Analysis
          16.3.4. Financial Overview
          16.3.5. Strategic Overview
    16.4. AbbVie, Inc.
          16.4.1. Company Overview
          16.4.2. Product Portfolio
          16.4.3. SWOT Analysis
          16.4.4. Financial Overview
          16.4.5. Strategic Overview
    16.5. C.H. Boehringer Sohn AG & Ko. KG.
          16.5.1. Company Overview
          16.5.2. Product Portfolio
          16.5.3. SWOT Analysis
          16.5.4. Financial Overview
          16.5.5. Strategic Overview          

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the healthcare regulations initiated by administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures